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Plain English summary
Cystic fibrosis (CF) is the commonest life-limiting inherited disorder in the UK. It affects many parts of the body
including the lungs and gut leading to increased infection and problems digesting food. People with CF need to
undergo many treatments each day throughout their whole lives. These include tablets, inhalers and breathing
exercises, which are a huge burden, taking up several hours every day
It is therefore, really important that the treatments we give are supported by good evidence, usually gathered from
clinical trials. Unfortunately, we do not have good evidence for many of the CF treatments. We recently ran an
exercise known as a James Lind Alliance Priority Setting Partnership (JLA PSP) to find out which the CF community
feel are the top priority research questions. People with CF and those who look after them suggested questions to
be answered by clinical trials. Through a series of online surveys and workshops these were then shortlisted to give
a final top ten.
Due to infection risk people with CF are advised not to mix, this meant we had to do things differently to the usual
way JLA PSPs are carried out. We used videoconferencing to enable multiple people with CF to participate. Surveys
were accessible online and promoted through social media.
Abstract
Background The James Lind Alliance (JLA) method is well recognised for setting research priorities. The JLA
approach involves a combination of surveys and workshop interactions between patients, carers and health care
professionals to identify and agree on a “top ten” list of research questions. Respiratory infection is one of the
hallmarks of cystic fibrosis (CF). To avoid cross infection, patients are advised not to meet face to face, preventing
us following standard JLA methodology. Here we describe adaptations made during our recent JLA Priority Setting
Partnership (PSP) in CF.
Methods We elicited and prioritised research questions, using sequential online surveys, promoted through social
media. People with CF participated in steering committee meetings and the final workshop, using
videoconferencing. Alterations to workshop methodology enabled participants attending in person and those
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joining remotely, to contribute equally. We also altered the JLA methodology to include “lone” questions, asked by
only one survey respondent. We are now working with the CF community to co-produce research projects that
answer these top ten.
Results There were 482 respondents, from 23 countries, who submitted 1080 questions. Increases in the number of
responses occurred just after promotion on social media. Use of videoconferencing enabled participation of
multiple people with CF and ensured participation from anywhere in the world, including hospital inpatients.
Inclusion of lone questions resulted in one being included in our top ten.
Conclusions There is no “one-size-fits-all” for patient involvement methodologies. Through altering the JLA
methods to fit our patient group we achieved wide participation. We believe that methods used in our project may
also be applied to future partnerships to increase participation, especially where people may be hospitalised or be
unable to travel. The methodology we are developing through the JLA PSP CF2 project may be useful for other
PSPs to follow.
Keywords: James Lind Alliance, Priority setting partnership, Cystic fibrosis, Videoconferencing, Patient involvement,
Social media, Cross infection
Background
Cystic Fibrosis (CF) is a life limiting inherited multi-system
disorder with a high treatment burden but relatively little
good quality evidence to guide treatment decisions [1]. In
the UK, 10,000 people have CF [2] and 70,000 adults and
children worldwide [3] are affected by the condition. This
leaves a relatively small population to take part in clinical
trials. It is therefore vital that the trials that do take place
are those of top priority to the CF community.
The James Lind Alliance (JLA) method is well respected
for setting research priorities. Their established method-
ology [4] involves a combination of surveys and workshop
interactions between patients, carers and health care profes-
sionals to identify and agree on a “top ten” list of priorities.
To date there have been over 50 Priority Setting Partner-
ships (PSP) across a wide field of medical conditions, con-
ducted worldwide, although the majority have taken place
within the UK [5].
Recently we undertook a JLA PSP in CF [6]. Respira-
tory infection is one of the hallmarks of CF and the risk
of cross infection with particular bacteria that people
with CF are more susceptible to, and with potentially
devastating consequences, means that patients are ad-
vised never to meet face to face [7]. The US CF Founda-
tion recommends that other approaches, such as
videoconferencing and the use of online materials [8] are
used to replace face-to-face contact where patient en-
gagement is important. Here we describe how we
adapted the JLA PSP process using video and online
methods to allow maximal participation and involve-
ment of patients, without putting them at risk. We be-
lieve that methods used in our project can be applied to
future partnerships to increase participation. This may
be especially useful in conditions where contributors
may be hospitalised or may be unable to travel due to
frailty or responsibilities as carers.
Methods
A James Lind Alliance Priority Setting Partnership (JLA
PSP) in CF was carried out at the University of Notting-
ham and commenced in March 2016. The top ten re-
search priorities for clinical research in CF were agreed
at a final workshop meeting in Jan 2017 [6]. Here we de-
scribe where we deviated from traditional JLA method-
ology in order to avoid cross infection and increase our
reach and participation.
JLA PSP methodology
The James Lind Alliance methodology is well defined
and usually follows a pathway which includes; develop-
ment of a steering group with face to face meetings; an
online/paper survey to gather uncertainties; organization
of responses and checking against current evidence; in-
terim priority setting to shorten the list of questions; a
final workshop with a mixture of small and whole group
discussions where all participants are present in person.
The workshop brings together representatives from both
the professional and lay communities who jointly refine
the final top ten priorities.
Below we outline where our methodology deviated
from the traditional methods and this is also represented
in Fig. 1.
Use of online surveys
We used two online surveys:
 An elicitation survey to collect research questions
from the patient and clinical community
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 A prioritisation survey, where the patient and
clinical communities ranked the final questions in
order of importance.
These surveys were designed to be completed easily on a
mobile device (e.g. smart phone). They collected a minimum
of demographic information to ensure they could be com-
pleted in a short time. The elicitation survey allowed up to
five free text research questions to be submitted, with a sug-
gested outcome measure for each (Fig. 2). The prioritisation
survey used a “drag and drop” interface to allow the partici-
pant to compile and rank their top ten research questions.
Social media promotion
A bespoke Twitter account was set up @questionCF with
the associated hashtag #questionCF. This was managed by
Fig. 1 Standard JLA methodology and adaptions made in the CF PSP. Standard JLA methodology is shown on the left hand side, adaptions for
the CF PSP shown on the right hand side
Fig. 2 Elicitation survey. This screen shot shows how research questions were collected. A free text box was used for people to leave their
answer in a narrative or story as well as by simple question format
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members of the steering group and aimed to promote the
online surveys and increase participation.
Videoconferencing
To prevent risk of spread of infection, people with CF are
advised not to meet face to face with others who have the
condition [8]. This presented us with a unique challenge as
the JLA Guidebook describes steering group meetings and
the final workshop occurring face to face. We used online
video conferencing methods through the BlueJeans™ plat-
form to avoid cross infection and widen participation
(Fig. 3a.). These were used both for steering committee
meetings and for the final workshop.
Final workshop adaptations
Prior to the workshop, test calls were carried out with
all those participants planning on joining remotely. This
allowed them to gain familiarity with the software and
any necessary trouble shooting to be undertaken. Basic
etiquette rules to facilitate the workshop such as muting
of microphones when not speaking to avoid background
noise and not having light source behind the participant
were also covered.
To ensure that those joining the final workshop re-
motely had their voice heard, a non-participating “room-
buddy” was present in person at the workshop. The “room
buddy” was a steering group member with the specific
task of advocacy for one remote participant.
Usually in JLA PSP workshops question cards are
moved around on tables to help the group decide on
rankings [4, 9]. The steering group decided this was not a
practical approach for our final workshop, as remote par-
ticipants were unable to see what was taking place in the
room. To give everyone an equal view of the questions
and their current ranking, an online real-time visual aid of
the questions was used and controlled by a “list-master” in
each room (Fig. 3b). This visual aid was shared with the
remote participants so that all participants had an equal
view of how the rankings were changing. The list-master
only moved a question when consensus was reached in
the small groups. All participants, whether attending in
person or remotely were sent an information pack prior to
the workshop including question cards (with details of the
candidate questions, numbers of ‘votes’ and breakdown of
lay versus profession votes) to make it more engaging and
easier for participants to play their part.
At the end of the process a short survey was sent out
to remote participants to find out about their experience
of participating via videoconferencing.
Lone questions
Through the elicitation survey, we asked participants to
tell us what they thought were the most important ques-
tions that needed answering by clinical research. We set
aside any questions which did not relate to treatment
uncertainties and those which had already been an-
swered. Prior to commencing this analysis we undertook
a systematic review of gaps in the evidence for treatment
decisions in CF which helped with this process [1]. We
sorted and grouped the resulting questions to produce a
shorter list of questions which could go through to the
ranking survey. The final list of questions to go to the
prioritisation survey was selected using a modified Del-
phi technique [10], conducted amongst all members of
the steering committee. Many PSPs discard questions
which were only suggested by one respondent at this stage
Fig. 3 Remote participation during the final workshop. a Photograph showing room set up for videoconferencing via the BlueJeansTM platform.
b Example of electronic question list. This was made in PowerPoint and sharable to each screen. Each question could be moved as it was
discussed with participants. c Quotes from feedback from remote participants
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[11, 12]. We did not discard questions simply because they
were suggested by one respondent only, as we felt that
every question deserved a chance of progressing.
Dissemination of final top ten
The final top ten questions were shared with the patient
and clinical community immediately after the final work-
shop, via our dedicated Twitter account (@questionCF).
We felt it was important to release the top ten immedi-
ately so that those who had contributed would find out
straight away. We produced a press release and key
stakeholders, such as the CF trust and NIHR, were up-
dated. Postcards with the Top ten were produced and
shared by steering group members with the patient com-
munity and with their clinical colleagues. Several discus-
sions were held with the National Institute for Health
Research (NIHR) to discuss taking ideas from the top 20
questions forward and funding opportunities for them.
Results
Through the use of online survey accessible to all, we
reached 2.5% of the UK’s CF population and 0.45% of
the world’s CF population [6].
Over the course of the PSP our @questionCF twitter
account gained 732 followers with 151,000 impressions
(total number of views of a conversation). Our hashtag
#questionCF was used 320 times with 1806 engagements
(the number of interactions people have with our con-
tent) (Fig. 4). Over half of our followers were UK based
but we have had interactions with accounts from North
America (32%), Australia (4%), the rest of Europe (6%)
and the Middle East (2%). Our twitter presence con-
tinues to grow with a current count (April 2019) of 1160
followers. Through twitter conversations with US coun-
terparts we forged a collaboration with researchers from
the CF Foundation.
The use of videoconferencing at steering group meetings
allowed two people with CF to participate in each meeting.
Had we not used this method, only one person with CF
could have attended the meeting in person. Our steering
group members were drawn from all over the UK and vid-
eoconferencing allowed colleagues to take part who could
not travel, or who had conflicting clinical commitments. Six
people attended the final workshop remotely, including one
who was a hospital inpatient and an observer from the Cys-
tic Fibrosis Foundation in the USA.
We evaluated participants’ experience of joining the
workshop remotely and five of the six remote participants
completed feedback; three said overall they were “very sat-
isfied” with the experience and two “satisfied”. Quotes
from feedback from the remote participants are shown in
Fig. 3c. Having test calls prior to the event were felt to be
very beneficial. Areas for improvement included ensuring
the setup of the room was as inclusive as possible and
using roaming microphones in group discussions to make
sure remote participants could hear clearly.
From a total of 39 questions classified as “lone ques-
tions”, six were carried forward to the public ranking
survey. One of these was in the final top ten at position
number four “Which therapies are effective in delaying
or preventing progression of lung disease in early life in
people with Cystic Fibrosis?”. Figure 5 shows the break-
down of how many individuals submitted the questions
that fed into the final top ten.
Our immediate dissemination of the Top 10 via Twitter™
proved very popular with the tweet of the Top 10 questions
gaining a potential reach of 59,061 people from the many
retweets and commenting on the post. From the press re-
lease several online news outlets picked up the story and the
CF trust produced a short video on the top ten. The post-
cards we produced have been very useful in providing inter-
ested parties with a “take home” visual guide to the Top 10.
We are pleased that following on from our discussions
with the NIHR, a Health Technology Assessment (HTA)
call was released in April 2018, with seven of the eight
areas with calls for funding related to our JLA top ten. A
further call to apply for NIHR funding to support clin-
ical research in CF, with a particular focus on the JLA
top 10, is planned.
Discussion
The importance of cross infection in CF has meant that our
PSP had to adapt the standard approach, described in the
JLA Handbook [4]. The use of online videoconferencing
Fig. 4 Twitter analytics for the @QuestionCF account during the course of the priority setting partnership. Impressions are the total number of
views of a conversation and engagements are the number of interactions people have with our content
Rowbotham et al. Research Involvement and Engagement            (2019) 5:24 Page 5 of 8
avoided the risk of cross infection; allowed participation by
those who could not travel (due to hospitalisation, distance
or family responsibilities); and minimized participation time.
The inclusion of remote participants throughout the process
worked well and feedback indicated that they were still able
to participate fully.
Whilst some of the issues we encountered were unique
to CF, there are many other instances where our adapted
methodology may enhance inclusivity. The Digital Tech-
nology for Mental Health PSP used an online Twitter™
chat to gather uncertainties amongst a population where
an online survey would be difficult for some participants
[13]. Other PSPs have used a combination of online sur-
veys, paper surveys, telephone conversations, focus groups
and face to face questioning at public events to gather
their uncertainties [14, 15]. Our PSP is the first to use re-
mote participation (C Whiting JLA NIHR personal com-
munication). Many conditions and life commitments
make it more difficult to travel to participate in a face to
face workshop and the use of a virtual workshop may
overcome this. The traditional methodology of a face to
face workshop may exclude people who feel uncomfort-
able in group situations and remote participation, from fa-
miliar surroundings, may alleviate this problem. This
allows engagement to be more balanced and not restricted
to a few vocal individuals.
In the planning and delivery of our workshop, we aimed
to ensure equality amongst the contributors to allow
everyone to have an equal say, regardless of whether they
were in the room or joining remotely. Future PSPs may be
able to take this process further and run virtual workshops
where all participants join remotely which may achieve
greater equality. In addition to widening access to partici-
pation, there could be other benefits such as cost savings
and reduced need for travel. However it is also likely that
PSP engagement through online surveys and social media
may not be comfortable for all potential participants (e.g.
the elderly). This may warrant a well-designed study to
compare the standard with an adapted methodology to
compare the two.
The demographic distribution of the CF population
means that most are familiar with social media and it is a
safe and popular way to interact with other people with
CF without fear of cross infection [16, 17]. Our use of
Twitter™ during this project increased our reach within
the CF community and allowed global participation and
collaboration. The number of people who interacted with
our questionCF posts showed that the CF community are
engaged in and passionate about research.
Many PSPs in other areas have discarded questions where
they are suggested by one respondent alone. When we
summarised our submitted questions, we kept lone ques-
tions in a separate list. We decided to allow these “lone”
questions to progress by adding them to the list of sum-
marised questions. One of these remained in the process all
the way to the final top ten. This would have been lost from
the top ten if we had followed the practice of earlier PSPs.
It highlights the importance of the steering group in guid-
ing the refining of questions and ensuring the process re-
mains true to what the CF community were telling us.
The NIHR plans to invite funding applications for CF re-
search based on our JLA top ten. We feel that co-produc-
tion of CF research should continue beyond setting
research priorities. Some of the top ten questions are still
very broad, for example: “What are the effective ways of
simplifying the treatment burden of people with Cystic Fi-
brosis?” To develop this question into a testable hypothesis
we need to understand:
 What are the most burdensome aspects of treatment
for people with CF?
 Does this vary with age, sex, and employment or
education status?
 Would it be acceptable to the person with CF to
have a reduction in treatment burden at the expense
of a more rapid decline in lung function?
Fig. 5 Breakdown of how many individual questions fed into the final top 10 questions. Each individual face represents one person submitting a
question, pink represents people with CF and their family and friends, green represents health care professionals
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We are currently undertaking a project to explore a
number of the top ten questions in greater depth in part-
nership with the CF community, using a combination of
online surveys and focus groups (known as JLA PSP CF2).
Our goal is to formulate testable hypotheses for clinical
research studies. Our protocol for this is published on the
University of Nottingham Research Repository [18].
Although the focus of the JLA is to further the evidence
base through clinical trials of treatment interventions,
other research methodologies, such as registry studies,
may also help resolve clinical uncertainties in CF. In the
US, this approach has been used by the US CF Founda-
tion, through the “Insight CF” survey [19]. This encour-
aged the patient community to provide questions which
could be answered through their registry.
Conclusions
There is no “one-size-fits-all” for patient involvement
methodologies. Through altering the JLA methods to fit
our patient group we increased participation. We believe
that methods used in our project may also be applied to
future partnerships to increase participation, especially
in conditions where people may be hospitalized, may be
unable or too busy to travel. The methodology we are
developing through JLA PSP CF2 / QuestionCF2 project
will be useful for other PSPs to follow to help turn their
top ten questions into fundable research projects.
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